In clinical work, we often see two different views of patients’ perception of hepatitis B treatment: one believes that hepatitis B will inevitably worsen and that more antiviral treatment will not help; the other believes that hepatitis B can be cured and always tries to find drugs that “completely remove the hepatitis B virus”. Although the two views are vastly different, they also reflect the lack of a comprehensive and correct understanding of the goals of hepatitis B treatment. Authoritative guidelines for hepatitis B treatment at home and abroad clearly state that the overall goal of hepatitis B treatment is long-term suppression of the virus and delaying the progression of the disease to cirrhosis and liver cancer; the results of numerous large clinical studies at home and abroad confirm that antiviral therapy can achieve this overall goal. This is a long-term result that requires professional doctors to treat hepatitis B patients for a long time. It can never be achieved in a hurry. Therefore, it also requires full awareness and thorough understanding by hepatitis B patients in order to better cooperate with their physicians, better control progression, improve quality of survival, reduce complications and prolong life. The new European Society of Hepatology and Asia-Pacific Hepatology Society guidelines for hepatitis B treatment also point out that: the basic goal of slow hepatitis B is viral suppression and normal transaminases during treatment, which can reduce the risk of cirrhosis and hepatocellular carcinoma, but long-term treatment is still needed; on the basis of the basic goal, if lasting e antigen serological conversion after drug discontinuation can be achieved, that is, long-term drug discontinuation without relapse, is the satisfactory endpoint of slow hepatitis B treatment, and reaching The risk of cirrhosis and hepatocellular carcinoma will be further reduced after reaching this endpoint; on the basis of the satisfactory endpoint, if surface antigen clearance is achieved, the ideal endpoint is reached, which is the closest endpoint to clinical cure at present, and the risk of cirrhosis and hepatocellular carcinoma is lowest after reaching this endpoint according to clinical research results. Simply put, the long-term threat of chronic hepatitis B is cirrhosis and hepatocellular carcinoma. We can effectively reduce the risk of cirrhosis and liver cancer by administering antiviral therapy. This should be the overall and long-term treatment goal for all patients with hepatitis B receiving antiviral therapy. Viral suppression during treatment and durable e antigen serological conversion or surface antigen clearance after drug discontinuation are the endpoints of treatment from basic control to clinical cure. We hope that each of our hepatitis B patients will fully recognize the disease, build up confidence in treatment, base on the overall goal, and ask a professional doctor to develop a long-term treatment plan according to their own situation to pursue a better treatment endpoint.